Objective To analyze the correlation between serum cadherin S100A10, fatty acid transporter-4(FABP4) and the clinicopathological characteristics and recurrence of breast cancer. Methods From February 2020 to February 2021, 121 patients with breast cancer admitted to the Comprehensive Diagnosis and Treatment Department of the First Affiliated Hospital of the Air Force Medical University of the People's Liberation Army were selected as the breast cancer group, and 75 women in hospital health examination during the same period were selected as the healthy control group. The serum S100A10 and FABP4 levels were detected, and the relationship between S100A10 and FABP4 and the clinicopathological characteristics of breast cancer was analyzed. Kaplan Meier survival curve was used to analyze the recurrence free survival time of breast cancer patients with different serum S100A10 and FABP4 levels, and Cox risk ratio regression was used to analyze the influencing factors of postoperative recurrence of breast cancer patients. Results Serum S100A10 and FABP4 levels in breast cancer group were higher than those in healthy control group(t/P=8.943/<0.001, 10.552/<0.001). The serum S100A10 and FABP4 levels of breast cancer patients with TNM stage III, low differentiation and Ki-67 positive were higher than those of TNM stage I-II, moderately and highly differentiated and Ki-67 negative patients(S100A10:t/P=19.607/<0.001, 20.176/<0.001, 27.815/<0.001; FABP4:t/P=49.936/<0.001, 68.449/<0.001, 141.910/<0.001), and the serum FABP4 levels of breast cancer patients with body mass index ≥ 25 kg/m2 were higher than those with body mass index<25 kg/m2(t/P=20.923/<0.001). During the follow-up period, a total of 5 cases were lost, with a median follow-up of 13(8-29) months. The recurrence free survival rate of patients with high-level S100A10 and FABP4 was lower than that of patients with low-level S100A10 and FABP4(χ2/P=4.183/0.041, 6.559/0.010). High TNM stage, S100A10 and FABP4 are risk factors for recurrence of breast cancer patients [HR(95%CI)=1.826(1.332-2.503), 1.141(1.022-1.273), 1.493(1.213-1.838)].Conclusion The levels of S100A10 and FABP4 in serum of breast cancer patients increased, which was related to the invasive pathological characteristics and recurrence of breast cancer.

Objective To analyze the expression levels of neurocilin-1(NRP-1) and programmed death ligand 1(PD-L1) in triple negative breast cancer(TNBC) tissues and their correlation and clinical significance. Methods Collect 40 cancer tissues and 10 corresponding adjacent tissues of TNBC patients who underwent surgical treatment at the Oncology Department of Xuzhou Medical University Affiliated Hospital from March 2012 to December 2014. Immunohistochemical methods were used to detect the expression levels of NRP-1 and PD-L1 in the cancer tissues and adjacent tissues, and the expression differences of NRP-1 and PD-L1 among different clinical and pathological features were analyzed; The Spearman hierarchy method was used to analyze the correlation between the two; Kaplan Meier method was used to draw survival curves, and a multivariate Cox regression model was used to analyze the prognostic factors related to TNBC patients. Results The expression levels of NRP-1 and PD-L1 proteins in TNBC cancer tissue were higher than those in adjacent tissues(P<0.01); The expression of NRP-1 is significantly correlated with tumor diameter and pathological grading(χ2/P=6.218/0.013,4.392/0.036).The expression of PD-L1 are significantly correlated with pathological grading ki67 levels(χ2/P=6.465/0.011,8.102/0.004).There is a positive correlation between the expression of NRP-1 and PD-L1(r=0.570,P<0.001). The median overall survival time of patients with high expression of NRP-1 and PD-L1 is lower than that of patients with low expression, respectively(χ2/P=14.510/0.002, 9.641/0.001), the median overall survival of patients with high expression of NRP-1 and PD-L1 was significantly lower than that of patients with low expression of NRP-1 and PD-L1(χ2=15.940,P=0.001). Cox regression analysis showed that high expression of PD-L1 was an independent risk factor for patient prognosis [HR(95%CI)=6.323(1.324-30.202),P=0.021].Conclusion The expression of NRP-1 and PD-L1 may be related to the occurrence, development, and prognosis of TNBC, and may become a new target for TNBC treatment. Combining NRP-1 and PD-L1 can be used to evaluate the severity of TNBC.

Objective To analyze the expression of miR-20a-5p and nuclear receptor subfamily 4 member 3(NR4A3) in bladder cancer(BC) and their relationship with clinicopathological characteristics and prognosis. Methods From December 2016 to January 2019, 30 patients with BC were selected from the Urology Department of the First People's Hospital of Qujing City for surgical treatment and their bladder cancer tissues and corresponding paracancerous tissues were collected. Real time fluorescence quantitative PCR(qRT-PCR) was used to detect the expression levels of miR-20a-5p and NR4A3 in BC cancer tissue, and to analyze the relationship between the expression of miR-20a-5p and NR4A3 and the clinical pathological characteristics of BC; Kaplan-Meier curve analysis of the relationship between miR-20a-5p, NR4A3 and the prognosis of BC patients; The Cox risk proportional regression model evaluates the influencing factors of prognosis in BC patients. Results Compared with adjacent tissues, the expression of miR-20a-5p in BC cancer tissue increased(t/P=7.013/<0.001), while the expression of NR4A3 decreased(t/P=9.658/<0.001). TargetScan website shows that there is a targeted relationship between miR-20a-5p and NR4A3, and Pearson correlation analysis shows a negative correlation between miR-20a-5p and NR4A3 expression in BC cancer tissue(r/P=-0.599/<0.001). Patients with pathological grade III, TNM stage III-IV, and BC without lymph node metastasis had higher miR-20a-5p than those with pathological grade I-II, TNM stage I-II, and lymph node metastasis(t/P=2.159/0.040, 2.157/0.040, 2.403/0.023). Patients with pathological grade III, TNM stage III-IV, and BC with lymph node metastasis had lower NR4A3 expression than those with pathological grade I-II, TNM stage I-II, and BC without lymph node metastasis, the differences were statistically significant(t/P=3.421/0.002, 5.445/<0.001,2.849/0.008). The overall 3-year survival rate of BC patients is 63.33%, and the 3-year survival rate of the miR-20a-5p high expression group is lower than that of the low expression group(χ2/P=4.474/0.034), the 3-year survival rate of the NR4A3 low expression group is lower than that of the high expression group(χ2/P=9.853/0.002);High expression of miR-20a-5p is an independent risk factor affecting the prognosis of BC patients [OR(95%CI)=2.028(1.764-2.895)].Conclusion The expression of miR-20a-5p increases and the expression of NR4A3 decreases in BC cancer tissue, which is related to the pathological grading, lymph node metastasis, TNM staging, and prognosis of BC. miR-20a-5p is an independent risk factor for the prognosis of BC patients.

Objective To analyze the dynamic changes of serum soluble intercellular adhesion molecule-1(sICAM-1) and soluble Fms-like tyrosine kinase 1(sFlt-1) in patients with skull base tumors after surgery and their correlation with postoperative cerebral vasospasm(CVS). Methods From April 2021 to August 2022, 123 patients with skull base tumors admitted to the Second Department of Neurosurgery of 321 Hospital were selected as the observation group. According to whether the patients developed CVS after surgery, they were divided into a subgroup of 71 patients without CVS and a subgroup of 52 patients with CVS. According to different degrees of CVS, the patients with CVS were divided into a mild subgroup of 22 cases, a moderate subgroup of 17 cases, and a severe subgroup of 13 cases. In addition, 120 health examination personnel from hospitals in the same period were selected as the health control group. Serum levels of sICAM-1 and sFlt-1 were measured in subjects. The diagnostic value of serum sICAM-1 and sFlt-1 on postoperative CVS in patients with skull base tumors was analyzed using the subject operating characteristic curve(ROC) 3 days after surgery. Results Compared with the healthy control group, the serum levels of sICAM-1 and sFlt-1 in the observation group significantly increased before and on the 3rd, 7th, and 14th days after surgery(F/P=1 583.113/<0.001, 849.906/<0.001); Compared with pre operation, the serum levels of sICAM-1 and sFlt-1 in the observation group significantly increased on the 3rd, 7th, and 14th days after operation(F/P=1 256.460/<0.001, 463.461/<0.001), and reached the highest value on the 7th day after operation; Compared with 7 days after surgery, the serum levels of sICAM-1 and sFlt-1 in the observation group were significantly lower on 14 days after surgery(P<0.05). Compared with the non-CVS subgroup, the levels of sICAM-1 and sFlt-1 in the patients with CVS subgroup significantly increased 3 days after surgery(t/P=11.688/<0.001, 6.887/<0.001), and the levels of sICAM-1 and sFlt-1 in the mild, moderate, and severe subgroups increased sequentially(F/P=18.820/<0.001, 29.845/<0.001); The ROC curve showed that the area under curve(AUC) of serum sICAM-1, sFlt-1, and their combination in the diagnosis of postoperative CVS in skull base tumors were 0.842, 0.821, and 0.924, respectively. The combined diagnostic efficacy of the two tests was higher than that of the single test(Z/P=2.029/0.042, 2.235/0.025). Conclusion The serum levels of sICAM-1 and sFlt-1 in patients with skull base tumors showed an upward trend before surgery and on the 3rd and 7th days after surgery, but decreased on the 14th day after surgery, which is related to the occurrence of CVS after surgery, and has certain diagnostic value for the occurrence of CVS after surgery for skull base tumors.